Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Ralph Defronzo
University of Texas Hlth Science Center, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
AstraZeneca
Payment for services (e.g., consulting fees, honoraria, paid authorship)
Entity is providing the study drug gratis
SGLT2 Inhibition and Stimulation of Endogenous Glucose Production
PROJECT NARRATIVE SGLT2 inhibitors (SGLTi) are a recently approved class of oral antidiabetic agents for the treatment of patients with type 2 diabetes mellitus (T2DM). However, we have demonstrated that their efficacy is offset by a ?paradoxical? increase in endogenous glucose production (EGP) that negates by ~50% the amount of glucose excreted in the urine. These results demonstrate the presence of a previously undescribed ?reno-hepatic? axis in which glucosuria sends a signal to the liver (and possibly to the kidney) to increase glucose production. In the present grant we will define the organ (liver and/or kidney) responsible for the increase in EGP and the mechanism(s) (stimulation of glucagon secretion, inhibition of insulin secretion, activation of the renal nerves) responsible for the rise in EGP. We also will examine whether a GLP-1 receptor agonist, by inhibiting glucagon/increasing insulin secretion, can block the rise in EGP following SGLT2 inhibition. If so, this would establish combined therapy with SGLT2i/GLP-1 RA as an early and effective strategy for the treatment of patients with T2DM.
Filed on October 16, 2017.
Tell us what you know about Ralph Defronzo's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Ralph Defronzo filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Ralph Defronzo | University of Texas Hlth Science Center | Conflict of Interest | AstraZeneca | $100,000 - $149,999 |
| Ralph Defronzo | University of Texas Hlth Science Center | Conflict of Interest | AstraZeneca | $100,000 - $149,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.